Ramoplanin

Ramoplanin

Ramoplanin is a type of antibiotic that is nonabsorbable and taken orally. It is a cyclic lipoglycodepsipeptide made up of 17 amino acids and is produced by Biosearch Italia. Ramoplanin works by binding to peptidoglycan in bacterial cell walls, which disrupts their synthesis.From: Kucers’ The Use of Antibiotics [2017], Investigational drug therapies currently in early-stage clinical development for the treatment of clostridioides (clostridium) difficile infection [2019]

View Chapter

Purchase Book

Published in M. Lindsay Grayson, Sara E. Cosgrove, Suzanne M. Crowe, M. Lindsay Grayson, William Hope, James S. McCarthy, John Mills, Johan W. Mouton, David L. Paterson, Kucers’ The Use of Antibiotics, 2017

Ed J. Kuijper

Ramoplanin (A 16686, A 16686A, MDL 62198, NTI-851) is a novel oral nonabsorbable 17-amino-acid cyclic lipoglycodepsipeptide antibiotic from Biosearch Italia. Cyclic lipodepsipeptides (see Chapter 45, Daptomycin) contain one or more ester bonds along with the amide bonds and have emerged as promising candidates for the development of new antibiotics. Ramoplanin is an antibiotic complex first identified in 1984 that was isolated from the fermentation broth of Actinoplanes spp. ATCC 33076. It is a mixture of three closely related compounds, ramoplanin A1–A3, which differ only in the acyl group attached to the Asn-1 N-terminus; ramoplanin A2 is the most abundant (Shin et al., 2004). The empirical formula is C106H170ClN21O30, and the molecular weight is 2254. The chemical structure of ramoplanin is shown in Figure 49.1.

Clostridium difficile infection in oncology patients: epidemiology, pathophysiology, risk factors, diagnosis, and treatment

View Article

Journal Information

Published in Hospital Practice, 2018

Omar Abughanimeh, Ayman Qasrawi, Osama Kaddourah, Laith Al Momani, Mouhanna Abu Ghanimeh

Ramoplanin is a glycolipodepsipeptide antibiotic that works by blocking peptidoglycan synthesis, thus affecting the bacterial cell wall [58,95]. In vitro, it adheres to spores, a function that also contributes to its activity against infection [97]. It was used to treat vancomycin-resistant enterococci but then noticed to have effect on CDI [58].. Freeman et al. [98] performed a study on hamsters with CDI showing similar efficacy between ramoplanin and vancomycin.

Ramoplanin

Explore chapters and articles related to this topic

Ramoplanin

Clostridium difficile infection in oncology patients: epidemiology, pathophysiology, risk factors, diagnosis, and treatment